EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Arterial hypertension associated with PARPi: A meta‐analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study

Clémence Blaize, Ellina Surtouque, Jonaz Font iD, Charles Dolladille iD, Sophie Postel-Vinay, Angélique Da Silva, Joachim Alexandre, Pierre-Marie Morice iD

Fundamental & Clinical Pharmacology · 2024

DOI: 10.1111/fcp.12984 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Fundamental & Clinical Pharmacology, 2024. Verfasst von Clémence Blaize und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Caen-Normandy University Hospital, Caen, France. Hauptthemen laut MEDLINE: Hypertension, Randomized Controlled Trials as Topic, Pharmacovigilance, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Arterial hypertension has been recently reported from randomized controlled trials (RCTs) assessing poly (ADP‐ribose) polymerase inhibitor (PARPi).

Objective

In a context of increasing use of PARPi, it is crucial to properly assess risk and incidence of this adverse event for clinical practice.

Methods

We performed a systematic review and meta‐analysis in MEDLINE, Cochrane CENTRAL and ClinicalTrials.gov up to January 4, 2023 with an ongoing surveillance up to June 7, 2023. RCTs comparing PARPi to placebo in adult patients with solid tumors were included if hypertension was reported. The primary outcome was the summary risk ratio (RR, with 95% CIs) of any hypertension of PARPi class in placebo RCTs. Secondary outcomes were the summary risk and incidence of hypertension of each individual PARPi. To provide clinical features of PARPi‐associated hypertension, we independently queried the WHO's pharmacovigilance database, up to September 1, 2022.

Results

In total, 41 placebo RCTs ( n = 15 264 adult patients) were included. PARPi class was not associated with an increased risk of hypertension compared with placebo. In individual analyses, the risk of hypertension was lower with olaparib than placebo (RR 0.77 [95% CI: 0.68–0.86], P < 0.01; I 2 = 19%, χ 2 P = 0.26). Niraparib monotherapy increased the risk of any (RR 2.84 [95% CI: 1.76–4.57], P < 0.01; I 2 = 66%, χ 2 P = 0.01) hypertension with a summary incidence of 19.87% (95% CI: 15.23–25.50). In real‐life setting, niraparib‐associated hypertension occurs within 20 days and was serious in 66%. Co‐prescription of at least one antihypertensive or therapy‐induced hypertension was reported in 20.5% or 14.4% of cases, respectively.

Conclusions

In a context of extensive assessment of niraparib in combination, these data reinforce the need of a close monitoring of this adverse event to preserve its clinical benefit on patients' survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionRandomized Controlled Trials as TopicPharmacovigilancePoly(ADP-ribose) Polymerase InhibitorsHumansWorld Health OrganizationNeoplasms

Stichwörter der Autor:innen

PARPiarterial hypertensionmeta‐analysispharmacovigilanceplacebo

Substanzen

Poly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology, Caen-Normandy University Hospital, Caen, France.
  • Normandie Univ, UNICAEN, INSERM U1086 'Interdisciplinary Research Unit for Cancers Prevention and Treatment' (ANTICIPE), Caen, France.
  • Department of Cardiology, Caen-Normandy University Hospital, Caen, France.
  • PICARO Cardio-Oncology Program, Department of Pharmacology, Caen-Normandy University Hospital, Caen, France.
  • European Research Council (ERC) StG Team, Inserm Unit U981, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
  • Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.

ORCID-Profile: Jonaz Font, Charles Dolladille, Pierre-Marie Morice

Zitieren

APA

Blaize, C., Surtouque, E., Font, J., Dolladille, C., Postel-Vinay, S., Da Silva, A., Alexandre, J., & Morice, P. M. (2024). Arterial hypertension associated with PARPi: A meta‐analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12984

Vancouver

Blaize C, Surtouque E, Font J, Dolladille C, Postel-Vinay S, Da Silva A, et al. Arterial hypertension associated with PARPi: A meta‐analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study. Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.12984

BibTeX
@article{Blaize2024,
  author = {Blaize, Clémence and Surtouque, Ellina and Font, Jonaz and Dolladille, Charles and Postel-Vinay, Sophie and Da Silva, Angélique and Alexandre, Joachim and Morice, Pierre-Marie},
  title = {Arterial hypertension associated with PARPi: A meta‐analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/fcp.12984}
}
Kostenlos starten →